| abstract |
The present invention provides a pharmaceutical composition for the treatment of type 2 diabetes in mammals including human beings, wherein the pharmaceutical composition contains (3aS, 5s, 6aR)-5-(2-((2S, 4S)-2-cyano-4-fluoropyrrolidin-1-yl)-2-oxo-ethylamino)-N, N, 5-trimethyl-hexahydro-cyclopenta[C]pyrrole-2(1H)-carboxamide or its pharmaceutically acceptable salts and rosiglitazone or pioglitazone or their pharmaceutically acceptable salts, preparation method thereof and the use of the pharmaceutical composition in manufacture of medicaments for treating type 2 diabetes in mammals including human beings. |